# A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

> **NCT07700875** · PHASE2 · COMPLETED · sponsor: **Wuhan Createrna Science and Technology Co., Ltd** · enrollment: 391 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** QR12000 Compound Tablets 75 mg
- **DRUG:** QR12000 Compound Tablets 75 mg placebo
- **DRUG:** QR12000 Compound Tablets 150 mg
- **DRUG:** QR12000 Compound Tablets 150 mg placebo
- **DRUG:** QR01019 potassium salt 50 mg
- **DRUG:** QR01019 potassium salt 50 mg placebo
- **DRUG:** Sacubitril / valsartan 200 mg
- **DRUG:** Sacubitril / valsartan 200 mg placebo
- **DRUG:** Valsartan 160 mg
- **DRUG:** Valsartan 160 mg placebo

## Key facts

- **NCT ID:** NCT07700875
- **Lead sponsor:** Wuhan Createrna Science and Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-29
- **Primary completion:** 2023-08-20
- **Final completion:** 2023-09-11
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700875, "A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*